Enleofen Bio focuses on developing safe and effective antibody therapeutics for multiple diseases, with a particular emphasis on fibrotic human diseases. The company was founded as a spin-out from National Heart Centre Singapore, SingHealth, and Duke-NUS Medical School with Series A funding. Enleofen aims to develop lead antibodies for clinical trials within two years to create a drug that can treat diseases with no current treatment options. Visit their website for more information.